CN110944982A - 奥扎莫德盐酸盐的晶型及其制备方法 - Google Patents

奥扎莫德盐酸盐的晶型及其制备方法 Download PDF

Info

Publication number
CN110944982A
CN110944982A CN201880047898.4A CN201880047898A CN110944982A CN 110944982 A CN110944982 A CN 110944982A CN 201880047898 A CN201880047898 A CN 201880047898A CN 110944982 A CN110944982 A CN 110944982A
Authority
CN
China
Prior art keywords
hydrochloride
preparation
degrees
crystal form
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880047898.4A
Other languages
English (en)
Inventor
陈敏华
张炎锋
翟晓婷
鄢楷强
杨朝惠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptos LLC
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Publication of CN110944982A publication Critical patent/CN110944982A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及奥扎莫德盐酸盐的晶型及其制备方法。本发明提供的奥扎莫德盐酸盐的晶型可用于治疗自身免疫疾病，特别是多发性硬化症和溃疡性结肠炎。本发明提供的奥扎莫德盐酸盐的晶型在溶解度、熔点、稳定性、溶出度、生物有效性以及加工性能、提纯等方面中的至少一方面上存在优势，为含奥扎莫德的药物制剂的制备提供了新的更好的选择，对于药物开发具有重要意义。
Figure DDA0002371847830000011

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201880047898.4A 2017-08-31 2018-08-23 奥扎莫德盐酸盐的晶型及其制备方法 Pending CN110944982A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017107686453 2017-08-31
CN201710768645 2017-08-31
PCT/CN2018/102034 WO2019042219A1 (zh) 2017-08-31 2018-08-23 奥扎莫德盐酸盐的晶型及其制备方法

Publications (1)

Publication Number Publication Date
CN110944982A true CN110944982A (zh) 2020-03-31

Family

ID=65524894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880047898.4A Pending CN110944982A (zh) 2017-08-31 2018-08-23 奥扎莫德盐酸盐的晶型及其制备方法

Country Status (4)

Country Link
US (1) US11117876B2 (zh)
EP (1) EP3677575A4 (zh)
CN (1) CN110944982A (zh)
WO (1) WO2019042219A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111223B2 (en) 2016-06-14 2021-09-07 Receptos Llc Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
WO2018033149A1 (zh) 2016-08-19 2018-02-22 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
WO2021197852A1 (en) 2020-04-02 2021-10-07 Synthon B.V. Crystalline form of ozanimod hydrochloride
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762100A (zh) * 2009-11-13 2012-10-31 瑞塞普托斯公司 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101582910B1 (ko) 2008-05-14 2016-01-08 더 스크립스 리서치 인스티튜트 스핑고신 포스페이트 수용체의 신규한 모듈레이터
EA021672B1 (ru) 2008-05-14 2015-08-31 Дзе Скриппс Рисёч Инститьют Модуляторы рецепторов сфингозин-1-фосфата и их применение
US20170165236A1 (en) 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
US20180016244A1 (en) 2015-04-06 2018-01-18 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
US11111223B2 (en) 2016-06-14 2021-09-07 Receptos Llc Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
WO2018033149A1 (zh) 2016-08-19 2018-02-22 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
WO2018049632A1 (zh) 2016-09-14 2018-03-22 杭州领业医药科技有限公司 奥扎莫德的晶型、其制备方法及药物组合物
CN109640982A (zh) 2016-09-14 2019-04-16 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
CN110612292A (zh) 2017-04-07 2019-12-24 杭州领业医药科技有限公司 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN107840830A (zh) * 2017-09-20 2018-03-27 广东东阳光药业有限公司 盐酸奥扎莫德无水晶型i

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762100A (zh) * 2009-11-13 2012-10-31 瑞塞普托斯公司 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法

Also Published As

Publication number Publication date
US20200339524A1 (en) 2020-10-29
EP3677575A1 (en) 2020-07-08
EP3677575A4 (en) 2020-07-15
WO2019042219A1 (zh) 2019-03-07
US11117876B2 (en) 2021-09-14

Similar Documents

Publication Publication Date Title
CN110944982A (zh) 奥扎莫德盐酸盐的晶型及其制备方法
CN110088088B (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
CN110799501B (zh) 一种食欲素受体拮抗剂的晶型及其制备方法和用途
CN111093668A (zh) Gsk1278863 的晶型及其制备方法和制药用途
CN111094290B (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
CN109641851B (zh) 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途
CN113242855A (zh) 他发米帝司的晶型及其制备方法和用途
AU2017373239B2 (en) Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
EP3530271A1 (en) Crystalline form ii of dextral oxiracetam, preparation method therefor and use thereof
CN110312705B (zh) Gft-505的晶型及其制备方法和用途
CN112770756A (zh) 一种Upadacitinib的晶型及其制备方法和用途
CN110621674B (zh) 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN108640910A (zh) 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
CN116802183A (zh) 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
WO2019105359A1 (zh) Acalabrutinib的晶型及其制备方法和用途
CN112076190A (zh) 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
CN111417624B (zh) Eb-1020的晶型及其制备方法和用途
WO2022048675A1 (zh) Risdiplam晶型及其制备方法和用途
EP4056182A1 (en) Crystal form of aprocitentan, preparation method therefor and use thereof
CN113173881B (zh) 羟尼酮的晶型及其制备方法和用途
CN113015722B (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
WO2018059420A1 (zh) E52862盐酸盐晶型h及其制备方法
WO2019011337A1 (zh) Qaw-039的晶型及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20201023

Address after: California, USA

Applicant after: RECEPTOS, Inc.

Address before: 215123 Biological Park B4301, No. 218 Xing Hu Street, Suzhou Industrial Park, Jiangsu

Applicant before: CRYSTAL PHARMACEUTICAL (SUZHOU) Co.,Ltd.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200331

WD01 Invention patent application deemed withdrawn after publication